BioXgen Announces Investment Offering and Webinar for Cardiac Patch Targeting Postoperative Atrial Fibrillation

BioXgen announced an open investment offering under Regulation Crowdfunding alongside a live investor webinar scheduled for April 30, 2026. The event will provide a demonstration of the company's cardiac patch on a heart model and feature presentations from leadership regarding development progress and regulatory milestones. The company is targeting postoperative atrial fibrillation, a complication affecting nearly half of the more than 500,000 Americans who undergo open-heart surgery annually, for which there is currently no FDA-approved prevention device.

The cardiac patch is intended for application at the surgical site, with BioXgen citing clinical data showing a tenfold reduction in postoperative AFib rates. The company reports the device is fully developed and that an FDA pre-submission has been filed, marking a step toward final regulatory review. During the webinar, Dr. David Skinner and Dr. John Konhilas will present the device, explain its surgical application, discuss the clinical rationale, and answer live questions about the technology and the investment opportunity.

"This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery," said Dr. David Skinner, President and CEO of BioXgen. The current community investment round is being conducted pursuant to Regulation Crowdfunding, allowing eligible investors to participate as the company advances toward FDA clearance and commercialization. The webinar is designed to offer a detailed look at the device, the clinical problem it aims to solve, and the market opportunity around POAF prevention.

Attendees will be able to see the product, learn about the company's progress, and ask questions about the investment offering in an interactive setting. To learn more about the offering, visit https://invest.bioxgen.life. To attend the webinar, registration is available at https://dnagency.lpages.co/bioxgen-device-reveal-and-investor-update/. BioXgen has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained via the investment portal.